Get the Stockscreener App
8.07
0.88%
0.07
Pre-market:
5.40
-2.67
-33.09%
Kalaris Therapeutics Inc stock is traded at $8.07, with a volume of 14,063.
It is up +0.88% in the last 24 hours and up +0.00% over the past month.
See More
Previous Close:
$8.00
Open:
$8
24h Volume:
14,063
Relative Volume:
4.87
Market Cap:
$149.62M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-12.38%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$7.675
$8.40
1-Week Range:
$7.675
$9.91
52-Week Range:
$7.675
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics Inc
Sector
Industry
Phone
(617) 433-2605
Address
1100 WINTER STREET, WALTHAM
Compare KLRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
8.07 | 149.62M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalaris Therapeutics Inc Stock (KLRS) Latest News
ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - MarketScreener
ALVR Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - MarketScreener
The Law Offices of Vincent Wong Remind AlloVir Investors of a Lead Plaintiff Deadline of March 19, 2024 - MarketScreener
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionALVR - MarketScreener
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact Levi & Korsinsky - MarketScreener
ALLOVIR SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - Marketscreener.com
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 - Investing.com India
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 By Investing.com - Investing.com UK
Kalaris and AlloVir Inc. complete merger - Ophthalmology Times
Kalaris Therapeutics Announces Closing of Merger With AlloVir - VisionMonday.com
ALLOVIR, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts against AlloVir, Inc. - Marketscreener.com
Kalaris Therapeutics Completes Merger with AlloVir -March 19, 2025 at 04:18 am EDT - Marketscreener.com
AlloVir Merges with Kalaris Therapeutics, Inc. - TipRanks
Kalaris Therapeutics Completes Merger with AlloVir, Advances Phase 1 Trial of TH103 for Neovascular Retina Diseases - Nasdaq
Kalaris Secures $100M War Chest for Revolutionary Macular Degeneration Treatment - StockTitan
Shootin' the Bull about cattle feeders - The Globe and Mail
Kalaris and AlloVir Announce Stockholder Approval of Merger - VisionMonday.com
Stockholders Approve Game-Changing Kalaris-AlloVir Merger: What This Means for Retinal Disease Treatment - StockTitan
Allovir, Inc. SEC 10-K Report - TradingView
Allovir’s chief accounting officer sells $967 in stock - Investing.com India
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc.ALVR - Business Wire
Allovir director Vikas Sinha sells $1,225 in stock - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATSG, CYTH, ALVR on Behalf of Shareholders - Finansavisen
AlloVir executes reverse stock split - Investing.com
Allovir stock plunges to 52-week low, touches $0.4 - Investing.com
AlloVir announces reverse stock split effective January 16 - Investing.com
AlloVir shareholders approve reverse stock split - Investing.com
AlloVir appoints new CEO following leadership shakeup - Investing.com
Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead - insights.citeline.com
AlloVir Ditches Immunotherapy, Teams Up with Kalaris to Take Over the $14 Billion Retinal Market - BioSpectrum Asia
Kalaris Therapeutics - The Pharma Letter
Kalaris to merge with AlloVir to become publicly traded company - World Pharmaceutical Frontiers
ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders - Business Wire
Class Action Filed Against AlloVir, Inc. (ALVR)March 19, 2024 Deadline to JoinContact Levi & Korsinsky - Marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Study examines connection between retinoblastoma and maternal smoking - Ophthalmology Times
Company unveils latest generation of assistive device for the legally blind - Ophthalmology Times
Ophthalmologist and former congressman John Cooksey dies at 80 - Ophthalmology Times
WVU receives $11 million COBRE grant for visual sciences research center - Ophthalmology Times
Faricimab FDA approval: Dr. Joshua Mali shares what this new therapy will mean to retina specialists - Ophthalmology Times
Bejeweled 17th century eyeglasses on block at Sotheby’s - Ophthalmology Times
AlloVir : Appoints Diana M. Brainard, M.D., as Chief Executive Officer, Effective May 17, 2021 - MarketScreener
Lexicon Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:LXRX - Benzinga
4D Molecular Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:FDMT - Benzinga
Alan S. Crandall, MD, remembered for impact on ophthalmology - Ophthalmology Times
ALVRAllovir, Inc. Latest Stock News & Market Updates - Stock Titan
COVID-19: Taking precautions with patients - Ophthalmology Times
Study: Therapy reduces proptosis, diplopia in TED - Ophthalmology Times
Dr. Shravani Mikkilineni presentation - Ophthalmology Times
Dr. Eileen S. Hwang Interview - Ophthalmology Times
Bowman layer transplantation effective in advanced keratoconus - Ophthalmology Times
Kalaris Therapeutics Inc Stock (KLRS) Financials Data
There is no financial data for Kalaris Therapeutics Inc (KLRS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):